Nano-Learning for Improving Compliance Among Older Adults With Sarcopenia

September 12, 2025 updated by: Rasha salah elsayed eweida, Alexandria University

Feasibility and Outcomes of Nano-Learning for Improving Compliance With Physical and Nutritional Guidelines and Reducing Late-Life Depression Among Older Adults With Sarcopenia in a Rural Province

Empirical evidence suggests that the use of short videos is associated with decreased feelings of loneliness and social isolation, thereby reducing depression among older adults . Platforms that allow users to showcase aspects of their own lives also serve as a significant avenue for achieving "happiness in old age" and enhancing social interactions with acquaintances . Therefore, this study aims to provide robust evidence on the effectiveness of nano-learning interventions, particularly in the context of sarcopenia, where addressing physical and psychological well-being has become increasingly critical among this cohort.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Nanolearning is an innovative pedagogical strategy that delivers content in highly focused, ultra-short learning experiences, often lasting less than two minutes, aimed at teaching a single skill or topic . Typically offered digitally through bite-sized video lessons or interactive practice exercises, it capitalizes on learners' preference for short-form content and informal learning methods, making knowledge acquisition more accessible and manageable for busy individuals. A defining feature of nano-learning is its brevity, with lessons intentionally kept under two minutes to align with contemporary learning habits, such as engaging with short-form videos on platforms like YouTube Shorts and TikTok . Empirical evidence suggests that the use of short videos is associated with decreased feelings of loneliness and social isolation, thereby reducing depression among older adults . Platforms that allow users to showcase aspects of their own lives also serve as a significant avenue for achieving "happiness in old age" and enhancing social interactions with acquaintances . Therefore, this study aims to provide robust evidence on the effectiveness of nano-learning interventions, particularly in the context of sarcopenia, where addressing physical and psychological well-being has become increasingly critical among this cohort.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
180

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Alexandria, Egypt, 21523
        • Faculty of nursing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants were eligible if they were 60 years or older,
  • had a diagnosis of sarcopenia based on a cut-off score of ≥3 of the Sarcopenia Geriatric Scale (SARCO-GS) (Rosas-Carrasco, 2023),
  • able to communicate effectively, and provided informed consent.

Exclusion Criteria:

  • Exclusion criteria encompassed severe cognitive impairment, debilitating chronic conditions, or unstable medical status that could hinder participation.
  • Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), with a cutoff score of 25 or below used to exclude participants (Nasreddine, 2005).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: interventional group
• Recruitment was conducted through face-to-face interviews in the clinic's waiting areas by the research team. These initial meetings, lasting approximately 20-30 minutes per participant, were essential for building rapport, obtaining anthropometric and other objective data, and ensuring informed consent. During the interview, the researchers explained the purpose and procedures of the study in detail, collected participants' mobile phone numbers, and administered the baseline (pretest) assessment using the study tools.
Behavioral: Nano-Learning interventional program
AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
No Intervention: control
they will be exposed only to the routine care provided by the nursing homes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
A Composite Physical Function (CPF) Scale
Time Frame: 2 month
is a validated tool designed to assess functional capacity in older adults across a continuum of daily activities. It consists of 12 items organized hierarchically, beginning with two basic activities of daily living (BADL) related to self-care, eating, and hygiene, followed by eight instrumental activities of daily living (IADL) that assess community functioning such as household chores, shopping, and mobility, and concluded with two advanced activities involving more demanding household tasks and strenuous physical exercise.
2 month

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Mini Nutritional Assessment-Short Form (MNA-SF)
Time Frame: 2 month
is a validated screening tool and one of the most widely recognized and well-studied tools for nutritional screening. It is designed to quickly identify older adults who are malnourished or at risk of malnutrition. As a shortened version of the full Mini Nutritional Assessment, it is widely used in clinical, community, and research settings due to its simplicity and time efficiency (Vellas et al., 2006).
2 month
Geriatric Depression Scale-Short Form (GDS-SF)
Time Frame: 2 month
is a 15-item self-report tool designed to evaluate depression and overall well-being in older adults. Respondents indicate how they have felt during the past week by choosing either "Yes" (scored as 1) or "No" (scored as 0). Scores are summed to yield a total ranging from 0 to 15, with 0-4 reflecting no depression, 5-8 indicating mild depression, 9-11 suggesting moderate depression, and 12-15 representing severe depression. In 2013, Elhusseini translated the scale into Arabic, confirming its validity and reliability (r = 0.70). The GDS-SF remains one of the most effective and widely used geriatric-specific screening instruments for detecting depression in older adults (Abd El Fatah et al., 2022; Stone et al., 2019).
2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Alexandria University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: rasha eweida, Damanhour University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 7, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 20, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 25, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 7, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 22, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 7/9/2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings